MedPharm, a provider of contract topical and transdermal product design and formulation development services, has introduced three new members to its board of directors.
MedPharm has announced the appointment following an investment by Ampersand Capital Partners in the company earlier this year.
Two of the new non-executive directors are members of the Ampersand investment team: David Parker, General Partner, and Trevor Wahlbrink, Partner.
The third non-exective director appointment is Patrick Walsh, who is currently the CEO of Avista Pharma Solutions, a pharmaceutical contract development and manufacturing organisation (CDMO) headquartered in Durham, North Carolina.
All have in-depth experience in the healthcare sector and have served on the boards of multiple CDMO businesses.
"We are very pleased to have David, Trevor and Patrick joining MedPharm’s board," said CEO Andy Muddle.
"They bring a wealth of experience which will be highly beneficial to MedPharm as it continues its impressive growth. Their wisdom and oversight will be invaluable to the business as we expand globally into new markets."
